Is Medline (MDLN) One of the Best Healthcare Stocks to Buy With the Highest Upside Potential?
Key takeaways
- Is Medline (MDLN) One of the Best Healthcare Stocks to Buy With the Highest Upside Potential?
- (NASDAQ:MDLN) also received a rating update from Tigress Financial on May 13.
- (NASDAQ:MDLN) provides medical-surgical products and supply chain solutions.
Is Medline (MDLN) One of the Best Healthcare Stocks to Buy With the Highest Upside Potential? Noor Ul Ain Rehman Wed, June 10, 2026 at 12:26 AM GMT+7 1 min read MDLN Medline Inc. (NASDAQ:MDLN) is one of the best healthcare stocks to buy with highest upside potential. Barclays cut the price target on Medline Inc. (NASDAQ:MDLN) to $45 from $50 on June 1, maintaining an Overweight rating on the shares. The firm stated that it believes factors such as inflationary pressure weighing on the margin outlook, less upside to fiscal Q1 estimates, and two secondaries have brought the company’s valuation “to a more palatable level.” According to Barclays, the stock is “poised for multiple expansion post war”, and it expects the company to “continue racking up share in the interim.”
Medline Inc. (NASDAQ:MDLN) also received a rating update from Tigress Financial on May 13. The firm lifted the price target on the stock to $62 from $60 while maintaining a Buy rating on the shares. It stated that the company’s ongoing transition from a traditional medical distributor to “a data-rich, AI-enabled supply chain partner” creates “near-term noise,” but “a long-term buying opportunity.”
Medline Inc. (NASDAQ:MDLN) provides medical-surgical products and supply chain solutions. The company’s operations are divided into the Medline Brand and Supply Chain Solutions segments.